Skip to content

{ Category Archives: } Biotech Stocks To Watch

Shire sells cancer biz for $2.4bn

17-Apr-2018 By Flora Southey Shire has sold its oncology business to French firm Servier S.A.S as it looks to better align its long-term strategy. More

BCLI: PHASE 3 TRIAL IN ALS ENROLLING PATIENTS

BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) has enrolled the first patients in the Phase 3 clinical trial of NurOwn® (NCT03280056) for the treatment of amyotrophic lateral sclerosis (ALS). The trial is taking place at six leading U.S. Medical centers. It is a randomized, double blind, placebo controlled, multi-dose trial that is expected to enroll approximately 200…

Japan’s New Drug: One Pill May Stop The Flu in Just One Day

One day, you may be able to stop flu viruses in your body in just one day with just one pill. Based on an announcement yesterday, that day may be someday very soon in May in Japan. On Friday, Japanese pharmaceutical company Shionogi announced that the flu medication that they have developed, Xofluza, otherwise known…

BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech Showcase

HACKENSACK, N.J. and PETACH TIKVAH, Israel, Dec. 20, 2017 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer, will provide a corporate overview at the 10th Annual Biotech Showcase, being held on January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco, California.   more at: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2323496

IQVIA: new article out “Heralding the Era of Human Data Science”

IQVIA, the recently formed merger of IMS Health and Quintiles, just announced publication of ““Heralding the Era of Human Data Science”.   “Human Data Science is a revolutionary new way to harness advances in technology, analytics and, above all, human ingenuity to help you pursue improvements in health outcomes.” More at:  https://www.iqvia.com/~/media/IQVIA/PDFS/AccessPoint/A1-from-IQVIA-AccessPoint-14-ORB1824_F.pdf